ClinicalTrials.gov record
Completed Phase 2 Interventional

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

ClinicalTrials.gov ID: NCT00004061

Public ClinicalTrials.gov record NCT00004061. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Double-Blind, Placebo-Controlled Trial of Recombinant Human Keratinocyte Growth Factor (rHuKGF) in Patients With Hematologic Malignancies Undergoing Total Body Irradiation (TBI) and High-Dose Chemotherapy With Autologous Peripheral Blood

Study identification

NCT ID
NCT00004061
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Enrollment
111 participants

Conditions and interventions

Interventions

  • cyclophosphamide Drug
  • etoposide Drug
  • filgrastim Biological
  • ifosfamide Drug
  • palifermin Biological
  • peripheral blood stem cell transplantation Procedure
  • quality-of-life assessment Procedure
  • radiation therapy Radiation

Drug · Biological · Procedure + 1 more

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 1999
Primary completion
Apr 30, 2003
Completion
Nov 30, 2009
Last update posted
Jun 25, 2013

1999 – 2009

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Memorial Sloan-Kettering Cancer Center New York New York 10021

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00004061, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 25, 2013 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00004061 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →